Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Case Comprehensive Cancer Center
20 participants
May 19, 2020
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.
Eligibility
Inclusion Criteria4
- All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
- Subject must meet program eligibility criteria\* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
- HLA-identical related donor or unrelated human donor source with bone marrow graft.
- Subjects must provide a written informed consent.
Exclusion Criteria3
- History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
- Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
- Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04332341